A Phase 1 dose escalation trial of monotherapy IDE574
Latest Information Update: 15 Feb 2026
At a glance
- Drugs IDE 574 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 11 Feb 2026 According to IDEAYA Biosciences media release, the company obtained clearance of an IND application with the U.S. FDA in January 2026; target to initiate Phase 1 dose escalation trial in Q1 '26.
- 22 Dec 2025 New trial record
- 10 Dec 2025 According to IDEAYA Biosciences media release, the company has submitted the IND application to the USFDA for this Phase 1 dose escalation trial of monotherapy IDE574, which is expected to begin in 1Q 2026.